# Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece

> **NCT06247319** · — · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 250 (actual)

## Conditions studied

- Moderate Plaque Psoriasis
- Moderate Psoriasis
- Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06247319
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-29
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06247319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06247319, "Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06247319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*